Lisa Lancaster

5PUBLICATIONS
15CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Major global burdens of diseasePredictive and prognostic markersImmunogenetics (incl. genetic immunology)Nanotoxicology, health and safety
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Jul 05, 2022
The Antifibrotic Effects of Inhaled Treprostinil: An Emerging Option for ILD.

Martin Kolb, Stylianos E Orfanos, Chris Lambers

|Oct 06, 2021
Idiopathic pulmonary fibrosis: Physician and patient perspectives on the pathway to care from symptom recognition to diagnosis and disease burden.

Lisa Lancaster, Francesco Bonella, Yoshikazu Inoue

|Oct 22, 2020
Effects of Nintedanib on Quantitative Lung Fibrosis Score in Idiopathic Pulmonary Fibrosis.

Lisa Lancaster, Jonathan Goldin, Matthias Trampisch

|Jul 07, 2020
Time to diagnosis of idiopathic pulmonary fibrosis in the IPF-PRO Registry.

Laurie D Snyder, Christopher Mosher, Colin H Holtze

|Jun 11, 2019
Safety and survival data in patients with idiopathic pulmonary fibrosis treated with nintedanib: pooled data from six clinical trials.

Lisa Lancaster, Bruno Crestani, Paul Hernandez

Pageof 1

Frequent Collaborators

1 joint publications

Laurie D Snyder

1 joint publications

Christopher Mosher

1 joint publications

Grace Hyun Kim

1 joint publications

Jonathan Ilowite